



## Preferred Drug List

### NEW DRUG REVIEW

**Proprietary Name:** Onglyza™

**Common Name:** Saxagliptin

**PDL Category:** Diabetic - Other

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Januvia®	Non-Preferred

#### Summary

**Indications and Usage:** Adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes Mellitus. <sup>1</sup>

**Mechanism of Action:** Competitive dipeptidyl peptidase-4 (DDP4) inhibitor that slows the inactivation of incretin hormones, thus increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations. <sup>1</sup>

**Dosage Forms:** Tablets: 2.5mg and 5mg

**Recommended Dosage:** Recommended dose is 2.5mf or 5mg once daily regardless of meals. 2.5mg daily is the recommended dose for patients with moderate or severe renal impairment, end-stage renal disease, and those taking strong cytochrome P450 3A4/5 inhibitors. <sup>1</sup>

**Common Adverse Drug Reactions:** Upper respiratory tract infection, urinary tract infection, headache. <sup>1</sup>

**Contraindications:** None. <sup>1</sup>

**Manufacturer:** Bristol-Myers Squibb

**Analysis:** Onglyza™ is the second oral DDP4 inhibitor indicated to improve glycemic control in adults with Type 2 Diabetes Mellitus. Onglyza™ may be used as monotherapy or in combination with other commonly used anti-diabetic medications- metformin, thiazolidinediones, and sulfonylureas. Onglyza™ lowers A1c without an increased risk of hypoglycemia or weight gain. Onglyza™ was compared only to placebo in the clinical trials for monotherapy. In clinical trials, Onglyza™ when used as monotherapy reduced A1c by 0.6%, compared to 1.5% for metformin, 1.5% for sulfonylureas, and 0.5-1.4% for thiazolidinediones. Preferred alternatives appear on the Preferred Drug List, which have similar clinical efficacy and are more cost effective. Therefore, it is recommended that Onglyza™ be added to the Preferred Drug List as a non-preferred drug.

**IME Recommendation:**  Preferred Drug  Recommended Drug  
 Non-Preferred Drug  Non-Recommended Drug  
 Non-Preferred Drug with Conditions

1. Onglyza™ [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2009.